The Effectiveness of mirogabalin on peripheral neuropathy among patients treated with oxaliplatin

The Effectiveness of mirogabalin on oxaliplatin-induced peripheral neuropathy: A Multicenter phase 2 study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041210094

Enrollment

Registered

2021-11-01

Start date

2021-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheralneuropathicpain Chemotherapy-induced peripheral neuropathy

Interventions

Administer mirogabalin for 42 days.

C000598618

mirogabalin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received oxaliplatin for the treatment of colorectal cancer, and tingling scores of 4 or more on the NRS scale in the hands or feet at the time of enrollment.

Exclusion criteria

Exclusion criteria: Patients with peripheral neuropathy caused by other diseases at the time of registration, with concomitant diabetes mellitus for whom neuropathy is a concern at the time of enrollment, and patients who have started, discontinued, or had a dose change of 10% or more of duloxetine, acetaminophen, NSAIDs, high-dose aspirin, or opioids within 14 days of enrollment.

Design outcomes

Primary

Measure	Time frame
Tingling 30% improvement rate	—

Secondary

Measure	Time frame
Change in NRS for Tingling, Numbness, and Pain from baseline	—

Contacts

Public ContactDaichi Watanabe

Gifu University Hospital

watayaku@gifu-u.ac.jp+81-582306000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026